Published in Eur J Clin Pharmacol on January 01, 1981
Identification of trichlormethiazide as a Mdr1a/b gene expression enhancer via a dual secretion-based promoter assay. Pharmacol Res Perspect (2015) 0.75
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology (2007) 3.17
Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications. Ann Pharmacother (1993) 2.02
The binding of drugs by plasma proteins. J Pharm Sci (1968) 1.69
Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry (1995) 1.63
Normal circulating adult human red blood cells contain inactive NOS proteins. J Lab Clin Med (2000) 1.62
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am (1994) 1.62
Detection of oxacillin-resistant staphylococci by the AutoMicrobic system. J Clin Microbiol (1983) 1.53
Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Mult Scler (2009) 1.52
A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry (2005) 1.50
Novel method for studying protein binding. J Pharm Sci (1968) 1.43
Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother (1995) 1.41
A poison education program for primary school. Vet Hum Toxicol (1984) 1.27
Liquid and solid potassium chloride: bioavailability and safety. Pharmacotherapy (1985) 1.21
Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry (1984) 1.18
Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics (1999) 1.08
The application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage forms. J Control Release (1999) 1.02
Differentiation of Rhizobium japonicum strain derivatives by antibiotic sensitivity patterns, lectin binding, and utilization of biochemicals. Can J Microbiol (1980) 1.01
Intolerance to volume expansion: a theorized mechanism for the development of preeclampsia. Obstet Gynecol (1998) 1.01
Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int Suppl (1983) 1.01
Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry (1999) 1.01
Solubility versus electrostatics: what determines lipid/protein interaction in lung surfactant. Biophys J (2007) 1.00
Dialysis catheter-induced superior vena cava syndrome and downhill esophageal varices. Clin Nephrol (2007) 0.98
Genetic structure of populations of Rhizoctonia solani anastomosis group-1 IA from soybean in Brazil. Phytopathology (2008) 0.96
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care (2000) 0.95
Relating formulation variables to in vitro dissolution using an artificial neural network. Pharm Dev Technol (1997) 0.93
Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther (2002) 0.91
Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis (2001) 0.91
Evaluation of the effectiveness of two support surfaces following myocutaneous flap surgery. Adv Wound Care (1995) 0.90
Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis (2000) 0.90
Composition and mechanics of mesenteric resistance arteries from pregnant rats. Am J Physiol (1992) 0.89
A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol (2001) 0.88
Labor induction with a prenatal diagnosis of fetal macrosomia. J Matern Fetal Med (1997) 0.88
Interaction of sulfate ion with a critical tyrosine residue in yeast phosphoglycerate kinase detected through the tetranitromethane reaction. FEBS Lett (1976) 0.86
The impact of socioeconomic and demographic factors on the utilization of smoking cessation medications in patients hospitalized with cardiovascular disease in Nova Scotia, Canada. J Clin Pharm Ther (2005) 0.85
Phenytoin I: in vitro-in vivo correlation for 100-mg phenytoin sodium capsules. J Pharm Sci (1983) 0.84
Influence of lipid saturation grade and headgroup charge: a refined lung surfactant adsorption model. Biophys J (2008) 0.84
In vivo-in vitro correlations with a commercial dissolution simulator II: papaverine, phenytoin, and sulfisoxazole. J Pharm Sci (1983) 0.83
Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme. Clin Sci Mol Med Suppl (1975) 0.83
The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharm Drug Dispos (1989) 0.83
Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach. Biopharm Drug Dispos (2000) 0.83
In vivo-in vitro correlations with a commercial dissolution simulator. I: Methenamine, nitrofurantoin, and chlorothiazide. J Pharm Sci (1981) 0.83
An enzyme hydrolyzing methylated inhibitors of nitric oxide synthase is present in circulating human red blood cells. Free Radic Res (2001) 0.82
Evaluation of enzyme immunoassay, radioassay, and radioimmunoassay of serum methotrexate, as compared with liquid chromatography. Clin Chem (1980) 0.81
Utilization-focused evaluation: evaluating the effectiveness of a hospital nursing orientation program. J Nurses Staff Dev (2002) 0.81
Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay. Ther Drug Monit (1985) 0.81
The effect of raising gastric pH with ranitidine on the absorption and elimination of theophylline from a sustained-release theophylline tablet. Pharm Res (1991) 0.81
High-pressure liquid chromatographic assay for griseofulvin in plasma. J Pharm Sci (1979) 0.81
Rapid, precise, turbidometric assay for low levels of ampicillin in serum after single-dose oral administration. Antimicrob Agents Chemother (1974) 0.81
Impact of a limited fluoroquinolone reimbursement policy on antimicrobial prescription claims. Ann Pharmacother (2001) 0.81
Role-effectiveness of the pharmacist in the treatment of hemodialysis patients. Am J Hosp Pharm (1978) 0.80
Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs. Drug Metab Dispos (1999) 0.80
Dynamic dialysis as a method for studying protein binding. I. Factors affecting the kinetics of dialysis through a cellophane membrane. J Pharm Sci (1970) 0.79
Meprobamate. J Am Pharm Assoc (1977) 0.79
Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period. Am J Med Sci (1999) 0.79
Renal transplantation in secondary oxalosis. Transplantation (1988) 0.79
Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey. Can J Cardiol (1999) 0.79
Factors affecting erythropoietin production and correction of anemia in kidney transplant recipients. Clin Transplant (1994) 0.79
Binding of salicylate and sulfathiazole by whole blood constituents. J Pharm Sci (1976) 0.79
Hydrochlorothiazide. J Am Pharm Assoc (1976) 0.79
Relative bioavailability of meprobamate tablets in humans. J Pharm Sci (1978) 0.79
[Analgesic dosage with (S)-ketamine/propofol vs. (S)-ketamine/midazolam: sedation, stress response and hemodynamics--a controlled study of surgical intensive care patients]. Anasthesiol Intensivmed Notfallmed Schmerzther (2001) 0.78
Placental transfer of chloroquine in pregnant rabbits. Res Commun Chem Pathol Pharmacol (1983) 0.78
Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm (1986) 0.78
Xenon inhalation increases airway pressure in ventilated patients. Acta Anaesthesiol Scand (1999) 0.78
Drug Information Center network: need, effectiveness, and cost justification. Drug Intell Clin Pharm (1987) 0.78
Circadian rhythm in theophylline disposition during a constant-rate intravenous infusion of aminophylline in the dog. J Pharm Sci (1988) 0.78
Effect of pH on the in vitro dissolution and in vivo absorption of controlled-release theophylline in dogs. J Pharm Sci (1988) 0.77
Does low protein diet halt the progression of renal insufficiency? Clin Nephrol (1986) 0.77
The efficacy of nutrition support in infected patients with chronic renal failure. Pharmacotherapy (1991) 0.76
Absence of effect of stimulants on the phamacokinetics of desipramine in children. Pharmacotherapy (1999) 0.76
Hypotension during hemodialysis: role for nitric oxide. Am J Med Sci (1997) 0.75
Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. J Clin Pharmacol (1982) 0.75
Is there a problem with benzodiazepine prescribing in maritime Canada? Can Fam Physician (1985) 0.75
Tacrolimus in transplantation. Am J Health Syst Pharm (1995) 0.75
Critical questions concerning the validity of the Bayer study report of "Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration". Int J Clin Pharmacol Ther (2010) 0.75
How effective are disease-modifying drugs in delaying progression in relapsing-onset ms? Neurology (2008) 0.75
Erythromycin-cyclosporin interaction. Drug Intell Clin Pharm (1986) 0.75
Compliance with guidelines for monitoring aminoglycoside therapy. Can J Hosp Pharm (1983) 0.75
Halothane hepatitis in a renal transplant patient previously exposed to isoflurane. Ann Pharmacother (1993) 0.75
Dialyzability and pharmacokinetics of indomethacin in adult patients with end-stage renal disease. Drug Intell Clin Pharm (1986) 0.75
Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J (1983) 0.75
Ipecac syrup for poisonings at home: availability, compliance, and response monitored by telephone. Am J Hosp Pharm (1981) 0.75
Cost considerations of intravenously administered histamine2-receptor antagonists. DICP (1989) 0.75
Effect of vitamin C on the excretion of methotrexate. Cancer Treat Rep (1984) 0.75
Effect of coadministration of acyclovir and cyclosporine on kidney function and cyclosporine concentrations in renal transplant patients. DICP (1991) 0.75
Terfenadine, a nonsedating antihistamine. Drug Intell Clin Pharm (1985) 0.75
The comparative bioavailability of liquid, wax-matrix, and microencapsulated preparations of potassium chloride. J Clin Pharmacol (1986) 0.75
Cyclosporine absorption in two patients with short-bowel syndrome. Drug Intell Clin Pharm (1988) 0.75
Community awareness of the Poison Control Centre and ipecac syrup. Can J Public Health (1983) 0.75
Economic status of callers to a poison center. Am J Hosp Pharm (1981) 0.75
Therapeutic assessment of Slow-K and K-tab potassium chloride formulations in hypertensive patients treated with thiazide diuretics. Drug Intell Clin Pharm (1987) 0.75
Peritoneal dialysis in the treatment of acetohexamide-induced hypoglycemia. Am J Hosp Pharm (1977) 0.75
Folic acid dosage for chronic hemodialysis patients. Clin Pharmacol Ther (1975) 0.75
Clinical toxicology consultation by pharmacists. Am J Hosp Pharm (1979) 0.75
A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group. Orthopedics (1998) 0.75
Increased cyclosporine bioavailability from a microemulsion formulation in a liver transplant recipient. Ann Pharmacother (1994) 0.75
Evaluation of criteria for the recognition of Diphyllobothrium species. Trans Am Microsc Soc (1966) 0.75
Methods of controlling cephalosporin use in Canadian hospitals. Can J Hosp Pharm (1988) 0.75